MedPath

Zilovertamab

Generic Name
Zilovertamab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2485779-13-1
Unique Ingredient Identifier
FEH7RQ7B3J
Associated Conditions
-
Associated Therapies
-
menafn.com
·

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PIPELINE ASSESSMENT, 2024 IN-DEPTH INSIGHTS INTO THE CLINICAL TRIALS

DelveInsight's 2024 report highlights over 55 companies and 60+ drugs in the Chronic Lymphocytic Leukemia (CLL) pipeline, with therapies in advanced stages expected to launch soon. The CLL market is poised for growth due to rising incidence, aging populations, and novel therapies. Key players include TG Therapeutics, Loxo Oncology, and BeiGene, focusing on innovative treatments beyond traditional chemotherapy.
biospace.com
·

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ...

Oncternal Therapeutics announced updated Phase 1/2 data for ONCT-534 in relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC), showing BID dosing was well-tolerated with no Grade 3 or higher toxicities. One patient experienced a 50% reduction in PSA after increasing the dose to 300 mg BID, and CTC analysis indicated promising effects on AR-regulated genes. The company continues to explore strategic alternatives for its product candidates.
cgtlive.com
·

Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808

Oncternal Therapeutics is discontinuing its phase 1/2 ONCT-808-101 trial for ONCT-808, a CAR-T therapy targeting ROR1 in r/r aggressive B-cell lymphoma, due to capital requirements. ONCT-808 showed antitumor activity and long-term CAR T-cell persistence, but one patient died from shock complications. The company is also halting trials for ONCT-534, zilovertamab, and ONCT-216, and reducing its workforce to explore strategic alternatives.
© Copyright 2025. All Rights Reserved by MedPath